Search hospitals

>

Ohio

>

Cincinnati

University of Cincinnati

Claim this profile

Cincinnati, Ohio 45219

Global Leader in Stroke

Global Leader in Heart Failure

Conducts research for Cancer

Conducts research for Lung Cancer

Conducts research for Pulmonary Arterial Hypertension

727 reported clinical trials

63 medical researchers

Photo of University of Cincinnati in CincinnatiPhoto of University of Cincinnati in Cincinnati

Summary

University of Cincinnati is a medical facility located in Cincinnati, Ohio. This center is recognized for care of Stroke, Heart Failure, Cancer, Lung Cancer, Pulmonary Arterial Hypertension and other specialties. University of Cincinnati is involved with conducting 727 clinical trials across 1,055 conditions. There are 63 research doctors associated with this hospital, such as Davendra P. Sohal, Trisha Wise-Draper, MD,PhD, Emily Curran, MD, and Shuchi Gulati, MD FACP.

Top PIs

Clinical Trials running at University of Cincinnati

Ovarian Cancer

Multiple Myeloma

Chronic Lymphocytic Leukemia

Cystic Fibrosis

Non-Hodgkin's Lymphoma

Lung Cancer

Fallopian Tube Cancer

Cancer

Stroke

Depression

Image of trial facility.

Mirvetuximab + Bevacizumab

for Ovarian Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Recruiting

2 awards

Phase 3

Image of trial facility.

Sacituzumab Tirumotecan

for Ovarian Cancer

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and If people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

Recruiting

2 awards

Phase 3

5 criteria

Image of trial facility.

Rina-S

for Ovarian Cancer

This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo.

Recruiting

2 awards

Phase 3

4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Cincinnati?

Where is University of Cincinnati located?

Who should I call to ask about financial aid or insurance network?

What insurance does University of Cincinnati accept?

What awards or recognition has University of Cincinnati received?